{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:07:32Z","timestamp":1793747252253,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21977012"],"award-info":[{"award-number":["21977012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21572018"],"award-info":[{"award-number":["21572018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177011"],"award-info":[{"award-number":["22177011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007302","name":"Beijing University of Chemical Technology","doi-asserted-by":"publisher","award":["XK2020-06"],"award-info":[{"award-number":["XK2020-06"]}],"id":[{"id":"10.13039\/501100007302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118818","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:12:12Z","timestamp":1775315532000},"page":"118818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Structure-guided discovery of a potent 2-aryl-4-aminoquinazoline-based inhibitor overcoming osimertinib resistance driven by EGFR C797S mutation in NSCLC"],"prefix":"10.1016","volume":"311","author":[{"given":"Hao","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohua","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8378-8993","authenticated-orcid":false,"given":"Renzhong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0320-5509","authenticated-orcid":false,"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118818_bib1","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.ejmech.2026.118818_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.118818_bib3","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118818_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118818_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/sonc.2002.35646","article-title":"Epidermal growth factor receptor expression, signal pathway, and inhibitors in non\u2013small cell lung cancer","volume":"29","author":"Bunn","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118818_bib6","first-page":"569","article-title":"Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development","volume":"26","author":"Shantaram","year":"2007","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118818_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3892\/or.2023.8675","article-title":"The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer","volume":"51","author":"Cheng","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.118818_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102824","article-title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.118818_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118818_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102724","article-title":"Neoadjuvant EGFR-TKI therapy in Non-small cell lung cancer","volume":"126","author":"Grant","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.118818_bib11","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118818_bib12","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1021\/acs.jmedchem.2c01434","article-title":"Development of Furanopyrimidine-Based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118818_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"Mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118818_bib14","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118818_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/OTT.S23165","article-title":"Johnson. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC","author":"Agulnik","year":"2013","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.118818_bib16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of Non\u2013small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118818_bib17","first-page":"1070","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Wenjun","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118818_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118818_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17568919.2025.2485675","article-title":"Development of indole hybrids for potential lung cancer treatment-part I: nitrogen-containing six-membered aromatic heterocycles","volume":"17","author":"Zhao","year":"2025","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118818_bib20","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer","volume":"61","author":"Chen","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118818_bib21","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.ejmech.2026.118818_bib22","first-page":"743","article-title":"Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors","volume":"23","author":"Singh","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118818_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118818_bib24","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"13","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118818_bib25","article-title":"1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M\/C797S resistant NSCLC","volume":"31","author":"Schalm","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118818_bib26","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes osimertinib-resistant EGFR-Del19\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118818_bib27","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1002\/anie.201703389","article-title":"Discovery of EGFR(d746-750\/T790M\/C797S) Mutant-Selective Inhibitors via Structure-Based de Novo Design","volume":"56","author":"Park","year":"2017","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118818_bib28","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.3390\/ijms21239323","article-title":"Rational computational design of fourth-generation EGFR inhibitors to combat drug-resistant non-small cell lung cancer","volume":"21","author":"Park","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118818_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104848","article-title":"Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors","volume":"112","author":"Zhou","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118818_bib30","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.1021\/acs.jmedchem.8b01612","article-title":"Design and evaluation of potent EGFR inhibitors through the incorporation of macrocyclic polyamine moieties into the 4-anilinoquinazoline scaffold","volume":"61","author":"Ju","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118818_bib32","doi-asserted-by":"crossref","first-page":"20531","DOI":"10.1021\/acs.jmedchem.4c01975","article-title":"Design, synthesis, and biological evaluation of novel diaminopyrimidine macrocycles as fourth generation reversible EGFR inhibitors that overcome clinical resistance to osimertinib mediated by C797S mutation","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118818_bib33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2026.118818_bib34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4939-2809-5_18","article-title":"Analysis of cell proliferation and homeostasis using EdU labeling","volume":"1323","author":"Flomerfelt","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118818_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12935-022-02801-w","article-title":"Current methods for studying metastatic potential of tumor cells","volume":"22","author":"Bouchalova","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2026.118818_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118818_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFR-independent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118818_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:45:36Z","timestamp":1781271936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"alternative-id":["S0223523426002631"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118818","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided discovery of a potent 2-aryl-4-aminoquinazoline-based inhibitor overcoming osimertinib resistance driven by EGFR C797S mutation in NSCLC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118818"}}